Navigation Links
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced completion of the company's Phase 1 clinical trial of AM103, Amira's internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response.

AM103 and AM803 are novel inhibitors of 5-lipoxygenase-activiting protein (FLAP) that have demonstrated potential to treat asthma and cardiovascular disease (CVD) by preventing the synthesis of leukotrienes (LT), which trigger inflammation. The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers who received AM103 or placebo for up to 11 days. The trial also assessed the pharmacodynamic properties of AM103, specifically its ability to inhibit LT production.

Results from the Phase 1 trial show that AM103 is safe and well-tolerated at doses up to 1,000 mg per day with no evidence of significant side effects. The systemic exposure of AM103 increased linearly from 50 mg to 1,000 mg.

Pharmacodynamic data demonstrated a robust and statistically significant reduction of LTB4 and LTE4 in a dose-dependent manner. "The results from this trial meet and even exceed our expectations for safety, and provide pharmacodynamic evidence consistent with this mechanism of action," said Peppi Prasit, Amira's chief scientific officer. "The half-life of up to 10 hours also gives us the opportunity to evaluate once-daily dosing in a Phase 2 trial, which we expect to start in 2008."

"Based on this very favorable profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2 study with AM103 in asthmatic patients," said Bob Baltera, Amira's chief executive
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... (PRWEB) April 18, 2015 Review of ... hosting a ‘Strategies for Success’ program for cataract surgeons ... meeting in San Diego, where eye surgeon Jeffrey L. ... this invitation-only event. Dr. Martin is the Managing Partner ... of Ophthalmology chose Dr. Martin to lead this year’s ...
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... York, NY (PRWEB) April 18, 2015 On ... Internal Security Threat Report , which they say, “exposes a ... how many new malware variants were introduced in 2014 - ... took for Zero Day threats to be identified and patched ... it is abundantly clear that doing business in a digital ...
(Date:4/18/2015)... 18, 2015 French physician and gastronome ... choices when he uttered, “Tell me what you eat, ... food to cope with stress or sadness has often ... indicates otherwise. Data collected from their Emotional ... to emotional eating, but for different reasons. , Collecting ...
(Date:4/17/2015)... Lynnwood, WA (PRWEB) April 17, 2015 ... seat cushions is introducing two new products to help ... seeking low back pain relief are the second most ... was our first product, designed specifically to help relieve ... the Comfort Cushion, and thousands of happy customers later, ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... face increased risk of fractures in later life, particularly ... of The Children's Hospital of Philadelphia and other researchers ... who had first experienced arthritis between ages one and ... a larger control group of 207,000 patients in a ...
... normal lung function and seem to perform lung function ... Similarly, male lung cancer patients were likely to end ... characterized by progressive deterioration in lung function. The results ... journal, a publication of the American College of Chest ...
... in a way that is powerful enough to change public ... continue, it could have a dangerous impact// on real-life situations ... issue of Neurology, the scientific journal of the American Academy ... foreign movies, only two out of 30 movies with characters ...
... in Montreal, Canada, has suggested that mothers who are not ... more attentive mothers. // ,These findings, from ... positive environment not only for the child, but for the ... that applies to our research - the best a father ...
... up by the Indian information technology (IT) sector. This move ... of a BPO firm. // The main aim of the body ... bolster overseas clients that India is safe for business. A lot ... strict surveillance. One such incidence is the arrest of three employees ...
... it was surprising to find that young people in the UK ... infections. // People between the age group of 15-24 years avoid ... As a result of observing the National Condom Week (NAT) health ... the British students. ,It surveyed 2,048 people aged 15 ...
Cached Medicine News:Health News:Male Lung Cancer Patients Less Likely To Perform Well in Lung Function Tests 2Health News:Movies Represent Coma In A Wrong Way 2Health News:Love Mom More 2
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... , April 17, 2015   IBA Molecular, ... radiopharmaceuticals, announced today that it has signed a definitive ... America, Inc. (IBAM NA), to Illinois Health and Science (IHS). ... as an independent company headquartered in Dulles, ... take advantage of new product and footprint synergies. IBA ...
(Date:4/17/2015)... , April 17, 2015 ... leading Life Science and High Technology company, today ... Pacific headquarters and state-of-the-art Cell Culture ... Park, the facility will provide customized support to ... scientific capabilities. "Our new Technical Center ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5
... CARMEL, Ind., Aug. 23, 2011 After several years ... device firms, Avant Healthcare Marketing has opened offices on ... expansion for the Midwest medical communications agency. ... Rod Julian, Strategic Brand Network Director for Avant. "But ...
... VeraLight Inc., the first company to develop an ... Healthcare Solutions Inc., a leading provider of in-pharmacy health ... the distribution of the SCOUT DS device in pharmacies ... Canada License Approval and European CE Mark, we have ...
Cached Medicine Technology:Avant Healthcare Marketing Announces West Coast Expansion 2VeraLight and Pear Healthcare Solutions Sign Canadian Distribution Agreement for SCOUT DS® Noninvasive Diabetes Screening Device 2
... ideal for evaluating a wide range of functions ... body. Often referred to at the "whole body" ... fetal, spinal cord and peripheral nerve studies, are ... 67 detector coils, covers a circular area approximately ...
... pH bone putty that contains calcium-based biocompatible ... decades in orthopedic surgery. These materials are ... of bone to help the patient heal ... to enhance bone regeneration, provide optimal osteo-conduction ...
... TAU Lead is a ... stimulation lead for temporary ... The unique shaft design ... straight or preformed stylets ...
... T is a quadripolar pacing ... pacing and monitoring during and ... 227 T features tines for ... allows safe and easy implantation ...
Medicine Products: